SouthState Corp’s Myriad Genetics MYGN Stock Holding History

SouthState Corp’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-50	Closed	-$266	–	1505
2025 Q2	$266	Buy	+50	New	+$295	﹤0.01%	1518

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

SouthState Corp's MYGN Position: Q3 2025 in Review

SouthState Corp sold out of Myriad Genetics (MYGN) in Q3 2025, closing a stake of 50 shares — an estimated $266 sold.

SouthState Corp first reported a position in MYGN in Q2 2025 and held it in 1 quarter. The position peaked at $266 in Q2 2025. 221 funds tracked by Wall St. Rank hold MYGN as of Q3 2025.

SouthState Corp reported no remaining Myriad Genetics position as of Q3 2025 after selling out during the quarter.
SouthState Corp sold 50 Myriad Genetics shares in Q3 2025, an estimated $266.
SouthState Corp first reported a position in Myriad Genetics in Q2 2025 and held it in 1 quarter.
SouthState Corp's Myriad Genetics position peaked at $266 in Q2 2025.
221 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2025.

Based on SouthState Corp's 13F filing for Q3 2025, filed 5 Nov 2025.